D-Plus Hemolytic Uremic Syndrome Overview

Save information for later
Sign Up

Learn About D-Plus Hemolytic Uremic Syndrome

What is the definition of D-Plus Hemolytic Uremic Syndrome?
D-plus (diarrhea positive) hemolytic uremic syndrome, also known as STEC hemolytic uremic syndrome, is a rare disease that affects children between one and ten years old which is characterized by low levels of red blood cells (hemolytic anemia), low platelets (thrombocytopenia), and an inability of the kidneys to process waste products from the blood (uremia). D-plus hemolytic uremic syndrome develops after certain bacterial infections, such as Escherichia. coli (E. coli) that cause diarrhea.
What are the symptoms of D-Plus Hemolytic Uremic Syndrome?
Symptoms of D-plus hemolytic uremic syndrome can be mild or severe and usually appear after an illness that is characterized by fever, abdominal cramps and pain, nausea, vomiting, and bloody diarrhea (gastroenteritis). Symptoms of D-plus hemolytic uremic syndrome may include paleness, irritability, weakness, reduced urinary output or no urine, lethargy, acute kidney injury, chronic kidney disease, protein in the urine, unexplained bruising, nosebleeds, high blood pressure, gallstones, neurological deficits, confusion, partial paralysis, seizures, coma, pancreatitis, and diabetes mellitus.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for D-Plus Hemolytic Uremic Syndrome?
Treatment for D-minus hemolytic uremic syndrome may include intravenous fluid and nutrition replacement, kidney or peritoneal dialysis, blood transfusion, vasodilators, medications, such as eculizumab and ultomiris (favulizumab-cwyz), plasma exchange (plasmapheresis), immunosuppressive therapy, or kidney transplantation.
Who are the top D-Plus Hemolytic Uremic Syndrome Local Doctors?
Dr. Matthew J. Ellis
Nephrology | Hospital Medicine
Dr. Matthew J. Ellis
Nephrology | Hospital Medicine

Duke Health Integrated Practice Inc

2351 Erwin Rd, 
Durham, NC 
 (26.0 mi)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Matthew Ellis is a Nephrologist and a Hospital Medicine provider in Durham, North Carolina. Dr. Ellis and is rated as an Advanced provider by MediFind in the treatment of D-Plus Hemolytic Uremic Syndrome. His top areas of expertise are Cytomegalovirus Infection, Cytomegalic Inclusion Disease, End-Stage Renal Disease (ESRD), Nephrosclerosis, and Kidney Transplant. Dr. Ellis is currently accepting new patients.

Dr. Thomas L. Ortel
Hematology
Dr. Thomas L. Ortel
Hematology

Duke Health Integrated Practice Inc

40 Duke Medicine Cir, 
Durham, NC 
 (25.8 mi)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Thomas Ortel is a Hematologist in Durham, North Carolina. Dr. Ortel and is rated as an Experienced provider by MediFind in the treatment of D-Plus Hemolytic Uremic Syndrome. His top areas of expertise are Venous Thromboembolism (VTE), Thrombocytopenia, Antiphospholipid Syndrome, Deep Vein Thrombosis, and Thalamotomy. Dr. Ortel is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Dr. Catherine R. Isaac
Internal Medicine
Dr. Catherine R. Isaac
Internal Medicine

Legacy Healthcare Services Inc

2701 Pickett Rd, 
Durham, NC 
 (26.7 mi)
919-419-9600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Catherine Isaac is an Internal Medicine provider in Durham, North Carolina. Dr. Isaac and is rated as an Experienced provider by MediFind in the treatment of D-Plus Hemolytic Uremic Syndrome. Her top areas of expertise are Melorheostosis with Osteopoikilosis, Osteopenia, Melorheostosis, and Hypertension. Dr. Isaac is currently accepting new patients.

View All Doctors
What are the latest D-Plus Hemolytic Uremic Syndrome Clinical Trials?
A Phase III Study to Evaluate the Efficacy of INM004 (Shiga Antitoxin) in Pediatric Patients With Shiga Toxin-producing Escherichia Coli-associated Hemolytic Uremic Syndrome.
A Phase III Study to Evaluate the Efficacy of INM004 (Shiga Antitoxin) in Pediatric Patients With Shiga Toxin-producing Escherichia Coli-associated Hemolytic Uremic Syndrome.
Enrollment Status: Recruiting
Publish Date: February 25, 2025
Intervention Type: Biological, Other
Study Phase: Phase 3

Summary: The objectives of this study are to evaluate the efficacy, safety, and pharmacokinetics of INM004 in pediatric patients with Hemolytic Uremic Syndrome associated to infection by Shiga toxin-producing Escherichia coli (STEC-HUS).

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Pediatric Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Pediatric Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
Who is this study for: Patients with Atypical Hemolytic Uremic Syndrome
Enrollment Status: Recruiting
Publish Date: February 05, 2025
Intervention Type: Drug
Study Drug: Crovalimab
Study Phase: Phase 3

Summary: This study aims to evaluate the efficacy and safety of crovalimab in pediatric participants with aHUS.

View All Clinical Trials